Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Gross Profit: 2014-2025

Historic Gross Profit for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $6.0 million.

  • CytomX Therapeutics' Gross Profit fell 82.16% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.6 million, marking a year-over-year decrease of 10.26%. This contributed to the annual value of $138.1 million for FY2024, which is 36.45% up from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Gross Profit is $6.0 million, which was down 68.04% from $18.7 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Gross Profit peaked at $50.9 million during Q1 2025, and registered a low of $6.0 million during Q3 2025.
  • In the last 3 years, CytomX Therapeutics' Gross Profit had a median value of $26.4 million in 2023 and averaged $28.6 million.
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 159.94% in 2023, then crashed by 82.16% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Gross Profit (Quarterly) stood at $11.1 million in 2021, then soared by 80.77% to $20.1 million in 2022, then spiked by 32.22% to $26.6 million in 2023, then surged by 43.17% to $38.1 million in 2024, then tumbled by 82.16% to $6.0 million in 2025.
  • Its Gross Profit stands at $6.0 million for Q3 2025, versus $18.7 million for Q2 2025 and $50.9 million for Q1 2025.